+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting a multinational phase III study to optimize therapy for children and adolescents with acute lymphoblastic leukemia ALL in complete remission who require allogeneic hematopoietic stem cell transplantation HSCT with a myeloablative conditioning regimen. The study aims to compare chemotherapy-based conditioning regimens with total body irradiation TBI combined with etoposide, focusing on treatment outcomes and side effects. This research addresses the need for safer conditioning options due to the significant long-term toxicities associated with TBI in growing patients. Participants receive different conditioning regimens before HSCT based on age, donor type, and country-specific protocols. The main options include TBI with etoposide for patients older than 4 years, and chemotherapy combinations such as fludarabine, thiotepa, treosulfan, busulfan, and cyclophosphamide for younger patients or those ineligible for TBI. Various donor types, including matched sibling donors, matched unrelated donors, and mismatched donors, are included, with additional treatments like ATG or T-cell depletion depending on donor matching. Throughout the study, participants undergo regular evaluations including survival monitoring and adverse event tracking for up to 10 years. Assessments focus on overall survival, event-free survival, relapse, and treatment-related toxicity. Data collection includes long-term follow-up to investigate factors affecting outcomes such as immune recovery, graft-versus-host disease, and pharmacogenomics. The total study duration can extend to several years to thoroughly assess late effects and survival rates.

Age: 1Month - 18YearsAll GendersPhase 2Phase 3
119 locations
U

Actively Recruiting

Researchers are evaluating the performance and safety of the GT Metabolic Magnet System, a device designed to create side-to-side compression anastomosis in the stomach andor small bowel. The study focuses on adults with gastrointestinal disorders such as partial small bowel obstruction, superior mesenteric artery syndrome SMAS, or gastric outlet obstruction GOO, conditions that involve physical or mechanical blockage of the gastrointestinal tract. These similarities make the Magnet System a potential surgical tool to address these issues as part of clinical treatment. Participants will receive treatment using the GT Metabolic Magnet System, which aims to form a magnetic compression anastomosis for intestinal diversion. The procedure involves placing magnets to create the anastomosis without the immediate need for lumen patency. The study includes monitoring the placement of the magnet on the first day, observing natural magnet passage, and assessing anastomosis patency over a 90-day period. This interventional study does not use blinding or randomization and focuses on the single experimental device. During the study, participants will be closely monitored through evaluations measuring magnet placement and passage, as well as the condition of the anastomosis up to 90 days post-procedure. Researchers will assess safety and device performance. Participants must follow study requirements, including surgical clearance and contraception use if applicable. The total duration includes the initial procedure and follow-up assessments to ensure proper device function and participant safety.

Age: 18Years +All GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are evaluating the effectiveness of two methods of providing positive pressure ventilation PPV to extremely premature infants during their first moments after birth. The study compares the standard manual T-piece resuscitator with a ventilator-delivered PPV V-PPV using nasal intermittent positive pressure ventilation NIPPV. This research aims to improve respiratory support in these vulnerable newborns to potentially reduce complications and the need for invasive procedures like intubation. The trial involves two groups one receiving PPV via a T-piece resuscitator connected to a face mask, and the other receiving PPV through a neonatal ventilator set in NIPPV mode delivered via a nasal mask or prongs. Both approaches provide PPV during the first 10 minutes after birth with standardized settings across sites. Each participating site is randomized to use one of these methods during neonatal resuscitation. Participants are extremely premature infants between 25 and 29 weeks gestational age who require PPV immediately after birth. Researchers will monitor major health outcomes including mortality, severe brain injury, and chronic lung disease up to around 50 weeks postmenstrual age. Additional assessments include the need for advanced resuscitation, duration of mechanical ventilation, and oxygen use at discharge. The study lasts from enrollment through hospital discharge or up to 50 weeks postmenstrual age, with safety and outcome data collected throughout.

Age: 25Weeks - 29WeeksAll GendersPhase Not Applicable
11 locations
C

Actively Recruiting

This trial investigates adults with obesity and type 2 diabetes, comparing two treatments to improve diabetes control. It evaluates the functional improvement of type 2 diabetes by using the Magnet System in a side-to-side duodeno-ileostomy surgery versus semaglutide medication. Participants have a body mass index between 30 and 40 kgm2 and a hemoglobin A1c level of at least 6.5%. The study is sponsored by GT Metabolic Solutions, Inc. and aims to assess how each treatment affects diabetes over time. Participants are randomly assigned to one of two groups one group receives the Magnet System device to create a duodeno-ileostomy through magnetic compression anastomosis, and the other group receives semaglutide medication as a weekly subcutaneous injection up to 2.4 mg or a dose tolerated based on side effects. The study prohibits additional metabolic or bariatric surgeries and the use of other GLP-1 receptor agonists during the study period. The treatment phase lasts up to one year with assessments scheduled accordingly. Throughout the study, participants will undergo evaluations including measurement of their hemoglobin A1c levels at day 360 to determine functional improvement in diabetes control. Researchers will monitor adherence to treatment, safety, and any side effects. Participants will provide informed consent and comply with follow-up visits and assessments for the full duration of the study, which extends to June 2028.

Age: 18Years +All GendersPhase Not Applicable
1 location